Elexacaftor–Tezacaftor–Ivacaftor Therapy for Cystic Fibrosis Patients with The F508del/Unknown Genotype

The new CFTR modulator combination, elexacaftor/tezacaftor/ivacaftor (Trikafta) was approved by the FDA in October 2019 for treatment of Cystic Fibrosis in patients 6 years of age or older who have at least one F508del mutation in one allele and a minimal-function or another F508del mutation in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Comegna, Marika, Terlizzi, Vito, Salvatore, Donatello, Colangelo, Carmela, Di Lullo, Antonella Miriam, Zollo, Immacolata, Taccetti, Giovanni, Castaldo, Giuseppe, Amato, Felice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8300667/
https://www.ncbi.nlm.nih.gov/pubmed/34356748
http://dx.doi.org/10.3390/antibiotics10070828

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8300667/
https://www.ncbi.nlm.nih.gov/pubmed/34356748
http://dx.doi.org/10.3390/antibiotics10070828

Ejemplares similares